Glenn van Dael
Director/Board Member at Rejuvenate Biomed
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Ann Beliën | M | - |
Rejuvenate Biomed
Rejuvenate Biomed Medical/Nursing ServicesHealth Services Rejuvenate Biomed is a clinical-stage platform and Belgian pipeline company founded in 2017 by Ann Belià « n. The company is committed to discovering and developing innovative combination drugs that can safely delay the onset of various age-related diseases. Rejuvenate Biomed has developed two proprietary drug discovery platforms, in silico combinagetm and in vivo celegagetm, to efficiently screen molecule libraries across a wide spectrum of age-related pathways. RJX-01, one of their drugs, is ready for a phase 2b clinical trial in sarcopenia, a musculoskeletal disease. The company is based on the Health Campus Limburg in Heusden-Zolder, BE. Ann Beliën has been the CEO since incorporation. | - |
Ajit Shetty | M | 77 |
Rejuvenate Biomed
Rejuvenate Biomed Medical/Nursing ServicesHealth Services Rejuvenate Biomed is a clinical-stage platform and Belgian pipeline company founded in 2017 by Ann Belià « n. The company is committed to discovering and developing innovative combination drugs that can safely delay the onset of various age-related diseases. Rejuvenate Biomed has developed two proprietary drug discovery platforms, in silico combinagetm and in vivo celegagetm, to efficiently screen molecule libraries across a wide spectrum of age-related pathways. RJX-01, one of their drugs, is ready for a phase 2b clinical trial in sarcopenia, a musculoskeletal disease. The company is based on the Health Campus Limburg in Heusden-Zolder, BE. Ann Beliën has been the CEO since incorporation. | 2 years |
Koen Desmedt | M | - |
Rejuvenate Biomed
Rejuvenate Biomed Medical/Nursing ServicesHealth Services Rejuvenate Biomed is a clinical-stage platform and Belgian pipeline company founded in 2017 by Ann Belià « n. The company is committed to discovering and developing innovative combination drugs that can safely delay the onset of various age-related diseases. Rejuvenate Biomed has developed two proprietary drug discovery platforms, in silico combinagetm and in vivo celegagetm, to efficiently screen molecule libraries across a wide spectrum of age-related pathways. RJX-01, one of their drugs, is ready for a phase 2b clinical trial in sarcopenia, a musculoskeletal disease. The company is based on the Health Campus Limburg in Heusden-Zolder, BE. Ann Beliën has been the CEO since incorporation. | - |
Lars Bastiaanse | M | - |
Rejuvenate Biomed
Rejuvenate Biomed Medical/Nursing ServicesHealth Services Rejuvenate Biomed is a clinical-stage platform and Belgian pipeline company founded in 2017 by Ann Belià « n. The company is committed to discovering and developing innovative combination drugs that can safely delay the onset of various age-related diseases. Rejuvenate Biomed has developed two proprietary drug discovery platforms, in silico combinagetm and in vivo celegagetm, to efficiently screen molecule libraries across a wide spectrum of age-related pathways. RJX-01, one of their drugs, is ready for a phase 2b clinical trial in sarcopenia, a musculoskeletal disease. The company is based on the Health Campus Limburg in Heusden-Zolder, BE. Ann Beliën has been the CEO since incorporation. | - |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
Belgium | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Glenn van Dael
- Personal Network